Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06531447
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
Sponsor: The National Center of Oncology, Azerbaijan
Conditions
Breast Cancer
Interventions
Cisplatin Cyclophosphamide Doxorubicin Gemcitabine Paclitaxel
Updated 2 times since 2024 Last updated: Jul 29, 2024 Started: May 31, 2014 Primary completion: Nov 30, 2017 Completion: May 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Breast Cancer and is currently ongoing. The National Center of Oncology, Azerbaijan leads this study, which shows 2 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
2 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- The National Center of Oncology, Azerbaijan
Data source: The National Center of Oncology, Azerbaijan
For direct contact, visit the study record on ClinicalTrials.gov .